Silva et al., 2021 - Google Patents
A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunitySilva et al., 2021
View PDF- Document ID
- 1477194893433595355
- Author
- Silva M
- Kato Y
- Melo M
- Phung I
- Freeman B
- Li Z
- Roh K
- Van Wijnbergen J
- Watkins H
- Enemuo C
- Hartwell B
- Chang J
- Xiao S
- Rodrigues K
- Cirelli K
- Li N
- Haupt S
- Aung A
- Cossette B
- Abraham W
- Kataria S
- Bastidas R
- Bhiman J
- Linde C
- Bloom N
- Groschel B
- Georgeson E
- Phelps N
- Thomas A
- Bals J
- Carnathan D
- Lingwood D
- Burton D
- Alter G
- Padera T
- Belcher A
- Schief W
- Silvestri G
- Ruprecht R
- Crotty S
- Irvine D
- Publication year
- Publication venue
- Science immunology
External Links
Snippet
Saponins are potent and safe vaccine adjuvants, but their mechanisms of action remain incompletely understood. Here, we explored the properties of several saponin formulations, including immune-stimulatory complexes (ISCOMs) formed by the self-assembly of saponin …
- 230000000240 adjuvant 0 title abstract description 172
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity | |
| Verma et al. | New-age vaccine adjuvants, their development, and future perspective | |
| Gao et al. | Virus-like particle, liposome, and polymeric particle-based vaccines against HIV-1 | |
| Wilson et al. | Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity | |
| Gause et al. | Immunological principles guiding the rational design of particles for vaccine delivery | |
| US9045556B2 (en) | Therapeutic agent for cancer | |
| Xu et al. | Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands | |
| US6749856B1 (en) | Mucosal cytotoxic T lymphocyte responses | |
| Volpatti et al. | Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity | |
| JP2007533644A (en) | Immunogenic compositions and vaccine development methods based on portions of HIV matrix proteins | |
| US12168051B2 (en) | Methods and compositions for stimulating immune response | |
| Rodrigues et al. | Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2 | |
| JP2017509642A (en) | Medicament for use in a method of inducing or prolonging a cellular cytotoxic immune response | |
| Berguer et al. | A polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants | |
| JP2016502508A (en) | Allogeneic autophagosome-enhancing composition for treatment of disease | |
| Kocabiyik et al. | Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract | |
| Wholey et al. | An Integrated Signaling Threshold Initiates IgG Response toward Virus-like Immunogens | |
| CN105451766A (en) | Vaccination strategy | |
| EP1011720B1 (en) | Mucosal cytotoxic t lymphocyte responses | |
| Kawai et al. | Lipid nanoparticle with 1, 2-Di-O-octadecenyl-3-trimethylammonium-propane as a component lipid confers potent responses of Th1 cells and antibody against vaccine antigen | |
| Quakkelaar et al. | IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation | |
| EP0391962A1 (en) | Compositions possessing immunostimulating properties and their applications in human and veterinary medecine | |
| EP1727563B1 (en) | Method for amplifying therapeutic vaccine activity | |
| Belcher et al. | A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity | |
| US20210015914A1 (en) | Methods and compositions related to accelerated humoral affinity |